Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
This tablet combines Olmesartan Medoxomil, a potent angiotensin II receptor blocker (ARB), with Amlodipine, a long-acting calcium channel blocker (CCB), to provide comprehensive blood pressure control. Olmesartan lowers blood pressure by blocking the action of angiotensin II on AT1 receptors, resulting in vasodilation and reduced vascular resistance. Amlodipine works by inhibiting calcium influx into vascular smooth muscle cells, leading to further relaxation of blood vessels and improved blood flow. The combination of these two agents offers dual benefits: Olmesartan counteracts the activation of the renin-angiotensin system, while Amlodipine prevents vascular constriction, making it highly effective for patients requiring combination therapy. This fixed-dose formulation is ideal for individuals who are inadequately controlled on monotherapy or require a simplified regimen to enhance adherence. By maintaining optimal blood pressure levels, this combination helps reduce the risk of stroke, heart attack, and other cardiovascular complications associated with hypertension.
Common side effects include headache, dizziness, fatigue, flushing, ankle swelling (edema), and mild gastrointestinal discomfort. Rarely, Olmesartan may cause low blood pressure (hypotension) or kidney function changes, while Amlodipine can lead to palpitations or gingival hyperplasia (gum overgrowth). In some patients, muscle cramps or allergic reactions may occur. Most side effects are mild and subside with continued therapy or dose adjustment.
Olmesartan Medoxomil 20 mg + Amlodipine 5 mg Tablet is indicated for the treatment of essential hypertension in adults. It is particularly beneficial in patients requiring combination therapy to achieve target blood pressure levels or those who do not respond adequately to a single agent.
This combination should be taken only under medical supervision. It is contraindicated in pregnancy, particularly in the second and third trimesters, due to the risk of fetal harm. Caution is advised in patients with severe liver impairment, kidney dysfunction, heart failure, or volume depletion. Alcohol should be limited as it may enhance the blood pressure-lowering effect and cause dizziness. The medication is not recommended during breastfeeding unless deemed essential by a physician. Do not discontinue the treatment abruptly without consulting your doctor, as it may cause a sudden increase in blood pressure. Regular blood pressure monitoring and follow-up are essential for safe and effective therapy.
Store the tablets in a cool, dry place at a temperature below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children and pets. Do not use after the expiry date mentioned on the pack.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Composition : Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 20 mg + Amlodipine 5 mg Tablet is a combination antihypertensive medication used for the management of high blood pressure (hypertension). It combines Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), with Amlodipine, a calcium channel blocker that relaxes blood vessels and improves blood flow. This dual-action therapy provides effective and sustained blood pressure control, making it highly relevant in the cardiology and cardiovascular care segment with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. Combination antihypertensive therapies are widely preferred for better BP control, ensuring regular prescriptions, repeat purchases, and long-term market stability.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription volume, long-term patient adherence, increasing cardiovascular healthcare needs, and continuous institutional demand, making this product a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.